Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP–1RA) in PatientS with Type 2 Diabetes—PROGRESS-DIABETES Study

This prospective, observational cohort study evaluates patient-reported outcomes (PRO’s) in patients initiating GLP-1 RA therapy in a real-world setting. Patients with type 2 diabetes initiating GLP-1 RA therapy as part of their usual treatment approach were enrolled from Ontario-based LMC Diabetes and Endocrinology clinics. Patients completed questionnaires assessing medication and device satisfaction and medication adherence at baseline and at follow-up (3-6 months). Standard clinical outcomes were collected. To date, 320 subjects have been enrolled: 187 dulaglutide (DULA), 110 liraglutide (LIRA), and 23 switching from LIRA to DULA. At baseline, PRO’s and clinical measures were similar between cohorts (mean age 54.2 ± 10.1 years; mean HbA1c 8.4 ± 1.5%). In this interim analysis of 110 completers to date (mean follow-up 3.3 months), there was a trend for the 77 DULA completers to have greater improvements in PRO scores compared to the 33 LIRA completers (Figure). To-date, DULA subjects had a 1.1 ± 1.0% reduction in HbA1c and 2.2 ± 3.3 kg reduction in weight. The LIRA subjects showed similar trends (1.2 ± 1.0% reduction in HbA1c and 2.4 ± 3.2 kg reduction in weight). Interim analysis of this real-world, specialist-led registry of patients initiating GLP-1 RA therapy showed similar improvements in PRO’s and clinical outcomes.